Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 5INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Dermatologic 2Breast 2Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Neurofibromatosis 1 6Neoplasm Metastasis 6Solid Tumours 5Neoplasms 5Melanoma 5Neurofibroma, Plexiform 4Lung Neoplasms 3Colorectal Neoplasms 3Breast Neoplasms 2Biliary Tract Neoplasms 2Uveal Melanoma 1Solid Tumors 1Renal Insufficiency 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Muscle Invasive Bladder Cancer 1Locally Advanced or Metastatic Solid Tumors 1Kidney Neoplasms 1Healthy Volunteers Pharmacokinetic Study 1Disease Progression 1Differentiated Thyroid Cancer 1Colonic Neoplasms 1Advanced Non Small Cell Lung Cancer 1Advanced Cancer 1

Interventions

Trastuzumab 209Paclitaxel 187Fulvestrant 161Capecitabine 150Docetaxel 136Letrozole 127exemestane 92palbociclib 76Anastrozole 75Cyclophosphamide 71Lapatinib 69Gemcitabine 66Bevacizumab 66pertuzumab 61pembrolizumab 60ribociclib 59Carboplatin 59abemaciclib 53eribulin 48Doxorubicin 45Vinorelbine 41Everolimus 41Ado-Trastuzumab Emtansine 41Tamoxifen 40130-nm albumin-bound paclitaxel 34Injections 31trastuzumab deruxtecan 30Albumin-Bound Paclitaxel 26olaparib 24Alpelisib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Breast Neoplasms × AZD 6244 × Clear all
NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

AstraZeneca

Phase 1 Completed
140 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT02586987 2019-11-18

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
58 enrolled
BreastDermatologicGastrointestinalThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Lung Neoplasms, Melanoma, Colorectal Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡